Homepage038290 • KOSDAQ
add
Macrogen Inc
Vorige slotkoers
â‚©Â 15.650,00
Dag-range
â‚©Â 15.530,00 - â‚©Â 15.690,00
Jaar-range
â‚©Â 14.700,00 - â‚©Â 24.600,00
Beurswaarde
169,67Â mld. KRW
Gem. volume
12,68K
Koers/winst
-
Dividendrendement
1,92%
Primaire beurs
KOSDAQ
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(KRW) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Opbrengst | 40,96Â mld. | 29,46% |
Bedrijfskosten | 16,98Â mld. | 24,32% |
Netto inkomsten | -2,22Â mld. | -3,18% |
Netto winstmarge | -5,42 | 20,29% |
Winst per aandeel | — | — |
EBITDA | -346,40Â mln. | -122,27% |
Effectief belastingtarief | 1,39% | — |
Balans
Totale activa
Totale passiva
(KRW) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 43,70Â mld. | 99,38% |
Totale activa | 332,81Â mld. | 26,75% |
Totale passiva | 161,36Â mld. | 50,90% |
Totaal aandelenvermogen | 171,45 mld. | — |
Uitstaande aandelen | 10,84 mln. | — |
Koers-boekwaardeverhouding | 1,09 | — |
Rendement op activa | -2,30% | — |
Rendement op kapitaal | -3,02% | — |
Kasstroom
Nettomutatie in liquide middelen
(KRW) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -2,22Â mld. | -3,18% |
Operationele kasstroom | 362,70Â mln. | 109,97% |
Kasstroom uit beleggingen | -8,90Â mld. | -43,15% |
Kasstroom uit financiering | 5,06Â mld. | 14,81% |
Nettomutatie in liquide middelen | -3,06Â mld. | 33,91% |
Vrije kasstroom | -2,12Â mld. | 88,42% |
Over
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
Opgericht
5 jun 1997
Website
Werknemers
500